Summary A LOOK AT ELAGOLIX FOR ENDOMETRIOSIS JULY 2018
|
|
- Conrad Wood
- 5 years ago
- Views:
Transcription
1 JULY 2018 WHAT IS ENDOMETRIOSIS? Endometriosis is a chronic gynecological condition with symptoms that include painful menstrual periods, nonmenstrual pelvic pain, and pain during intercourse, as well as infertility. Endometriosis affects between four and ten million women of reproductive age in the US. Pain associated with the condition can decrease quality of life by increasing depressive symptoms, reducing sexual satisfaction, and disrupting personal relations. TREATMENT OPTIONS Though available treatments have been shown to decrease the severity and frequency of patient symptoms, none appear to offer a cure or longterm relief. A range of treatment options are currently used, including: Nonsteroidal anti-inflammatory drugs and hormonal contraceptive therapy Gonadotropin-releasing hormone (GnRH) agonists (available by injection or intranasally) Aromatase inhibitors Various surgical procedures Elagolix (Orilissa TM, AbbVie) was approved in July 2018 for patients with endometriosis. It is a short-acting, oral GnRH antagonist. It works similarly to GnRH agonists, but, unlike agonists, does not cause an initial surge in hormones that can temporarily increase symptoms, and it and does not completely suppress estrogen. Both GnRH agonists and antagonists can cause low estrogen symptoms, such as hot flashes, as well as bone mineral density loss. Since endometriosis-related symptoms recur after stopping treatment, it remains to be determined whether elagolix is safe or effective for longterm use. Summary KEY FINDINGS The New England CEPAC voted that evidence was not adequate to determine whether elagolix offers a net health benefit compared to no treatment, or compared to treatment with either a GnRH agonist (leuprorelin acetate) or a hormonal contraceptive (depot medroxyprogesterone), due to limited and mixed evidence on clinical effectiveness and potential risks. AFFORDABILITY AND ACCESS ALERT Given that optimal clinical uptake at current estimated discount prices would lead to five-year costs far in excess of the $915 million threshold ICER is issuing an Access and Affordability Alert for elagolix. KEY POLICY RECOMMENDATIONS It is reasonable for insurers to develop prior authorization criteria for elagolix to ensure prudent use, based on known short-term side effects, and the lack of long-term data on safety and efficacy compared to other treatments. Manufacturers should engage with key stakeholders in a transparent process to evaluate fair pricing of new therapeutics based upon the added clinical benefit to patients. Patient organizations should band together to seek commitments from government research funding agencies and manufacturers to increase research for common conditions affecting women s health such as endometriosis. 1
2 Clinical Analyses ICER EVIDENCE RATINGS How strong is the evidence that elagolix improves outcomes in patients with endometriosis? Evidence on elagolix compared to no treatment was promising but inconclusive. While important clinical benefits in pain reduction were observed, potentially serious adverse events, such as increased bone mineral density loss and changes in cholesterol levels have not been fully evaluated. The FDA prescribing information also highlighted warnings about elevated liver function tests, suicidal ideation, and reduced ability to recognize pregnancy; therefore, the possibility of net harm cannot be ruled out. Evidence on elagolix compared to GnRH agonists, hormonal contraceptives, and aromatase inhibitors was insufficient to judge the net health benefit. KEY CLINICAL BENEFITS STUDIED IN CLINICAL TRIALS Elagolix Compared to Placebo Menstrual Pain Nonmenstrual Pelvic Pain Quality of Life High dose elagolix (200 mg twice daily) provided greater improvements in pain, quality of life, and decreased use of rescue opioids than the lower dose of elagolix (150 mg daily). Elagolix improved dysmenorrhea (pain during the menstrual cycle) to a greater degree than nonmenstrual pelvic pain although it provided some benefit for both types of pain. Compared to other therapies In two Phase II studies that compared elagolix to other treatments (leuprorelin acetate and depot medroxyprogesterone acetate), outcomes of elagolix at 150 mg daily were similar or inferior to comparator therapies. We found no data on elagolix versus aromatase inhibitors. 2
3 Clinical Analyses (continued) HARMS The most commonly reported side effects of elagolix are hot flash, headache, and nausea. Bone mineral density loss is significantly greater than with no treatment, particularly with the 200 mg twice daily dose. Changes in blood lipid profiles (elevated total cholesterol, LDL cholesterol, and triglycerides) may put women at higher risk for cardiovascular events. The FDA prescribing information includes a warning for elevated liver function tests and specifies that elagolix should not be used by patients with severe liver impairment. It also highlights warning for suicidal ideation and reduced ability to recognize pregnancy. The safety of elagolix use during pregnancy is uncertain. SOURCES OF UNCERTAINTY Trial Designs: Phase II and III studies of elagolix had major differences, including dosing, duration of use, primary endpoints, and outcome analysis. As a result, we were unable to perform indirect comparisons and cost-effectiveness modeling between elagolix and active comparators. Dosing Effects: The Phase III trials included a 200 mg twice a day dosing regimen that was not evaluated in prior trials. Evidence suggests a dose-response relationship with increased efficacy but also greater side effects. Duration of Treatment Response: Available evidence has evaluated elagolix versus placebo or active comparators only through three or six months. Given that endometriosis is a chronic condition with no available treatment demonstrating cure or long-term control of symptoms, how elagolix compares to other therapies over time and potentially with longterm use is uncertain. Outcome Measures: A variety of pain and functional status outcomes were used in the Phase II and III trials of elagolix. The primary patient-reported clinical response outcome of the Phase III trials was not previously used in trials, separate clinical response was reported for dysmenorrhea and nonmenstrual pelvic pain with no overall pain outcome. Comparator Data: Head-to-head data for elagolix versus comparators are limited to single Phase II studies, which had relatively small sample sizes, incomplete reporting and imbalances in baseline characteristics, short durations of follow-up, high attrition rates, and limited statistical testing. Long-term Side Effects: There is uncertainty regarding side effects with longer-term use and with respect to potential long-term harms, particularly decreases in bone mineral density that did not return to pre-treatment levels even after stopping treatment. 3
4 Economic Analyses LONG-TERM COST-EFFECTIVENESS At the assumed net price of $7,400, elagolix falls within commonly accepted thresholds for cost-effectiveness of $50,000-$150,000 when compared to other pain medications. Elagolix 200 mg twice daily, short-run: $126,800/QALY* Elagolix 200 mg twice daily, long run: $81,000/QALY *QALY: quality-adjusted life year Elagolix s cost-effectiveness was analyzed using a short-term decision tree (6 months) as well as a long-term (18 year) model in keeping with the average age of treatment initiation to menopause. Elagolix was modeled at the 200mg dose to capture the larger clinical benefit demonstrated in the trials; however, this was also associated with higher rates of side effects. VALUE-BASED PRICE BENCHMARKS What is a fair price for elagolix based on its value to patients and the health care system? ANNUAL WAC ANNUAL PRICE TO ACHIEVE $100,000 PER QALY THRESHOLD ANNUAL PRICE TO ACHIEVE $150,000 PER QALY THRESHOLD DISCOUNT FROM WAC REQUIRED TO REACH THRESHOLD PRICES Elagolix 200 mg Twice daily Short-run* $10,138 $5,800 $8,400 43% to 17% Elagolix 200 mg Twice daily Long-run* $10,138 $8,800 $12,800 14% to +26% *Economic analysis were conducted using a short-term decision tree (6 months) as well as a long-term (18 year) model in keeping with the average age of treatment initiation to menopause. 4
5 Economic Analyses (continued) How many patients can be treated with elagolix before crossing ICER s $915 million budget impact threshold? POTENTIAL SHORT-TERM BUDGET IMPACT The annual budget impact of treating the entire eligible population at elagolix s assumed net price ($7,400) was estimated at approximately $3.7 billion. The per patient budget impact versus other pain medications was approximately $4, % 25% can be treated At elagolix's assumed net price, however, only 25% of the eligible population cohort could be treated each year before the budget exceeded the ICER annual budget impact threshold of $915 million. cannot be treated AFFORDABILITY AND ACCESS ALERT Given that optimal clinical uptake at current estimated discount prices would lead to five-year costs far in excess of the $915 million threshold ICER is issuing an Access and Affordability Alert for elagolix. ICER's Access and Affordability Alert is intended to provide a signal to manufacturers, insurers, patient groups, and other stakeholders when the amount of added health care costs associated with these new treatments may be difficult for the health care system to absorb over the short term without displacing other needed services or contributing to rapid growth in health care insurance costs that threaten sustainable access to high-value care for all patients. ICER encourages all stakeholders to consider whether action should be taken to achieve additional price discounts, prioritize treatment access, find ways to reduce waste to provide additional resources, or take other policy steps to manage these budget implications. 5
6 Voting Results The New England CEPAC deliberated on key questions raised by ICER s report at a public meeting on July 14, More detail on the voting results is provided in the full report. CLINICAL EFFECTIVENESS During the meeting, the council voted that evidence was not adequate to determine whether elagolix offers a net health benefit compared to no treatment, or compared to treatment with either a GnRH agonist (leuprorelin acetate) or a hormonal contraceptive (depot medroxyprogesterone), due to limited and mixed evidence on clinical effectiveness and potential risks. LONG-TERM VALUE FOR MONEY The council did not vote on value, due to their finding that evidence is inadequate to determine that the clinical benefits of elagolix outweigh its unknown long-term risks. OTHER POTENTIAL BENEFITS AND CONTEXTUAL CONSIDERATIONS During the deliberation, panel members discussed the broader considerations around the significant impact endometriosis can have on women s quality of life, elagolix s availability as an oral agent, as well as other unique characteristics of the drug. They also noted the the uncertainty around the therapy s long-term side effects and clinical benefit, as elagolix use was limited to 6-12 months in clinical trials yet therapy intended to treat a chronic and disabling condition. 5
7 Policy Roundtable The Midwest CEPAC participated in a moderated policy discussion that included physicians, patient advocates, manufacturer representatives, and payer representatives. None of the resulting policy statements should be taken as a consensus view held by all participants. For a more detailed discussion, please see the full report. PAYERS It is reasonable for insurers to develop prior authorization criteria for elagolix to ensure prudent use, based on elagolix s known shortterm side effects, and the lack of long-term data on safety and efficacy compared to other wellestablished treatments. Prior authorization criteria should be based on clinical evidence, with input from clinical experts and patient groups. Options for specific elements of coverage criteria within insurance coverage policy include: Potential patient eligibility criteria: Premenopausal women with symptomatic endometriosis who have had inadequate relief after at least three months of first-line therapy with nonsteroidal anti-inflammatory meds (NSAIDs) and hormonal contraceptives. Potential provider criteria: Prescription only by a specialist in obstetrics/gynecology or reproductive endocrinology. Insurers should, however, consider the potential impact on access for some patients and consider options such as generalist consultation with specialists through telehealth. Potential limitations on initial length of coverage: Given the importance of monitoring for side effects, the initial coverage period may be limited to a prespecified period of time, e.g. six months, with requirements for clinical attestation of improvement and documentation of monitoring for lipid levels and bone density. MANUFACTURERS Manufacturers should engage with key stakeholders in a transparent process to evaluate fair pricing of new therapeutics based upon the added clinical benefit to patients. Manufacturer-sponsored research should enroll patients who reflect the population of patients commonly encountered in clinical practice and who are most likely to benefit from treatment. Manufacturers and researchers in endometriosis owe patients, clinicians, and insurers better information on the long-term comparative clinical effectiveness and value of innovative new therapies. They should take action to ensure that future studies directly compare elagolix with other treatment options using standardized research protocols that focus on outcomes that matter most to patients. PATIENT ORGANIZATIONS Patient organizations should band together to seek commitments from government research funding agencies and manufacturers to increase research, both basic and clinical, for common conditions affecting women s health such as endometriosis. 6
8 Policy Roundtable (continued) PROFESSIONAL SOCIETIES Professional societies should take steps to address and minimize potential conflicts of interest and to collaborate with patients and methodological experts on development of comprehensive, unbiased guidelines and educational outreach for patients with endometriosis. REGULATORS Regulators should require post-approval, long-term comparative outcomes studies for treatments, like elagolix, that are initially evaluated and approved in short-term randomized trials but for which long-term therapy would be expected for some patients. About ICER The Institute for Clinical and Economic Review (ICER) is an independent nonprofit research institute that produces reports analyzing the evidence on the effectiveness and value of drugs and other medical services. ICER s reports include evidence-based calculations of prices for new drugs that accurately reflect the degree of improvement expected in long-term patient outcomes, while also highlighting price levels that might contribute to unaffordable short-term cost growth for the overall health care system. ICER s reports incorporate extensive input from all stakeholders and are the subject of public hearings through three core programs: the California Technology Assessment Forum (CTAF), the Midwest Comparative Effectiveness Public Advisory Council (Midwest CEPAC) and the New England Comparative Effectiveness Public Advisory Council (New England CEPAC). These independent panels review ICER s reports at public meetings to deliberate on the evidence and develop recommendations for how patients, clinicians, insurers, and policymakers can improve the quality and value of health care. For more information about ICER, please visit ICER s website ( 7
For Tardive Dyskinesia
A LOOK AT VMAT2 INHIBITORS DECEMBER 2017 For Tardive Dyskinesia Tardive dyskinesia (TD) is a repetitive, involuntary movement disorder caused by prolonged use of medications that block the dopamine receptor,
More informationA LOOK AT CGRP INHIBITORS FOR MIGRAINE PREVENTION JUNE 2018
JUNE 2018 Overview: About Migraine WHAT IS MIGRAINE? Migraine is a common, recurrent headache disorder that affects approximately 20% of women and 6-10% of men in the US. Migraine attacks are characterized
More informationSummary A LOOK AT ANTIANDROGEN THERAPIES FOR NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER CASTRATION-RESISTANT PROSTATE CANCER TREATMENT OPTIONS
A LOOK AT ANTIANDROGEN THERAPIES FOR NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER OCTOBER 2018 Summary CASTRATION-RESISTANT PROSTATE CANCER Prostate cancer is the second most common cause of cancer
More informationSeptember 2017 A LOOK AT PARP INHIBITORS FOR OVARIAN CANCER. Drugs Under Review. ICER Evidence Ratings. Other Benefits. Value-Based Price Benchmarks
September 2017 Drugs Under Review ICER s report reviewed the clinical effectiveness and value of olaparib (Lynparza, AstraZeneca), rucaparib (Rubraca, Clovis Oncology), and niraparib (Zejula, Tesaro),as
More informationSummary A LOOK AT BIOLOGICS FOR ASTHMA DECEMBER 2018 KEY REPORT FINDINGS WHAT IS ASTHMA? TREATMENT OPTIONS KEY POLICY RECOMMENDATIONS
DECEMBER 2018 Summary WHAT IS ASTHMA? Asthma is a disorder that causes the airways of the lungs to narrow or become blocked, making it difficult to breathe. Exposure to certain triggers, such as allergens,
More informationIntroduction. Summary A LOOK AT CAR-T THERAPIES MARCH 2018 LEUKEMIA AND LYMPHOMA CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR-T) THERAPY
MARCH 2018 Introduction LEUKEMIA AND LYMPHOMA This review focuses on two types of B-cell cancers: childhood B-cell acute lymphoblastic leukemia (B-ALL), and aggressive B-cell non-hodgkin s lymphoma (NHL)
More informationFor Rheumatoid Arthritis
For Rheumatoid Arthritis APRIL 2017 NOTICE: On April 14, 2017 the FDA issued a complete response letter for baricitinib indicating that the FDA is unable to approve the application in its current form
More informationBackground AN UPDATED LOOK AT TREATMENTS FOR PLAQUE PSORIASIS JULY 2018 PLAQUE PSORIASIS TARGETED IMMUNOMODULATORS AS A TREATMENT OPTION
JULY 2018 Background PLAQUE PSORIASIS Plaque psoriasis is a common disease affecting 3% of the US population that causes itchy, red, scaly, raised lesions on the skin, most commonly on the elbows, knees,
More informationA LOOK AT ABUSE-DETERRENT OPIOIDS
JULY 2017 Drugs Under Review ICER s report reviewed evidence on ten abuse-deterrent formulations (ADF) of opioids. Nine of the drugs were extended release (ER) opioids, and one was immediate release (IR).
More informationElagolix for Treating Endometriosis
Elagolix for Treating Endometriosis Final Evidence Report August 03, 2018 Prepared for Institute for Clinical and Economic Review, 2018 ICER Staff/Consultants Steven J. Atlas, MD, MPH Director, Primary
More informationDiabetes Prevention Programs for Prediabetes
PROVEN BEST CHOICES Diabetes Prevention Programs recognized by the US Centers for Disease Control and Prevention (CDC) Diabetes Prevention Programs for Prediabetes What is a Proven Best Choice? The Proven
More informationORILISSA (elagolix) oral tablet
ORILISSA (elagolix) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage
More informationTreatment Options for Men with Low-Risk Prostate Cancer
PROVEN BEST CHOICES Active Surveillance Prostatectomy Brachytherapy LOWER-VALUE OPTIONS Intensity Modulated Radiation Therapy (IMRT) Proton Beam Therapy Treatment Options for Men with Low-Risk Prostate
More informationOrilissa (elagolix) NEW PRODUCT SLIDESHOW
Orilissa (elagolix) NEW PRODUCT SLIDESHOW Introduction Brand name: Orilissa Generic name: Elagolix Pharmacological class: GnRH antagonist Strength and Formulation: 150mg, 200mg; tabs Manufacturer: AbbVie
More informationNonpharmacologic Interventions for Treatment-Resistant Depression. Public Meeting December 9, 2011
Nonpharmacologic Interventions for Treatment-Resistant Depression Public Meeting December 9, 2011 New England CEPAC Goal: To improve the application of evidence to guide practice and policy in New England
More information10.2 Summary of the Votes and Considerations for Policy
CEPAC Voting and Policy Implications Summary Supplemental Screening for Women with Dense Breast Tissue December 13, 2013 The last CEPAC meeting addressed the comparative clinical effectiveness and value
More informationCurrent Landscape: Value Assessment Frameworks. Kimberly Westrich, MA Vice President, Health Services Research
Current Landscape: Value Assessment Frameworks Kimberly Westrich, MA Vice President, Health Services Research Updated June 2016 Background There are many aspects to the U.S. health care system, as well
More informationCTAF Overview. Agenda. Evidence Review. Insulin Degludec (Tresiba, Novo Nordisk) for the Treatment of Diabetes
CTAF Overview Insulin Degludec (Tresiba, Novo Nordisk) for the Treatment of Diabetes February 12, 2016 Core program of the Institute for Clinical and Economic Review (ICER) Goal: Help patients, clinicians,
More informationQUESTIONS FOR DELIBERATION. The general framework within which CEPAC discusses and votes on the evidence is shown below:
New England Comparative Effectiveness Public Advisory Council Public Meeting Durham, New Hampshire Treatments for Attention Deficit Hyperactivity Disorder June 1, 2012 DRAFT: May 2, 2012 Introduction QUESTIONS
More informationProcess for appraising orphan and ultra-orphan medicines and medicines developed specifically for rare diseases Effective from September 2015
Introduction Process for appraising orphan and ultra-orphan medicines and medicines developed specifically for rare diseases Effective from September 2015 From September 2015 the All Wales Medicines Strategy
More informationEVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT
differ and that they each has a unique mechanism of action. As such perc considered that it would be important for clinicians and patients to be able to choose either drug as a first-line treatment option.
More informationCombining Individualized Treatment Options with Patient-Clinician Dialogue
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationPCSK9 Inhibitors for Treatment of High Cholesterol. Public Meeting October 27, 2015
PCSK9 Inhibitors for Treatment of High Cholesterol Public Meeting October 27, 2015 Agenda Meeting Convened and Opening Remarks 10:00 AM- 10:15 AM Steven Pearson, MD, MSc, President, Institute for Clinical
More information- Linzagolix overall efficacy and safety maintained or improved at week 24
Final results of ObsEva SA Phase 2b EDELWEISS trial of Linzagolix show sustained efficacy and Bone Mineral Density safety, for the treatment of endometriosis-associated pain - Linzagolix overall efficacy
More informationAddressing Endometriosis with Your Patients: Combining Individualized Treatment Options with Patient-Clinician Dialogue
Addressing Endometriosis with Your Patients: Combining Individualized Treatment Options with Patient-Clinician Dialogue Objectives Describe the multiple symptoms of endometriosis and its varied presentation
More informationREFERENCE CODE GDHC015POA PUBLICAT ION DATE DECEM BER 2013
REFERENCE CODE GDHC015POA PUBLICAT ION DATE DECEM BER 2013 ENDOMETRIOSIS - Executive Summary The table below presents the key metrics for endometriosis therapeutics in the six major pharmaceutical markets
More informationNext Steps for Clinicians
Controversies in the Management of Patients with Type 2 Diabetes The New England Comparative Effectiveness Public Advisory Council An Action Guide for Type 2 Diabetes Management Next Steps for Clinicians
More information1. Comparative effectiveness of vedolizumab
Cost-effectiveness of vedolizumab (Entyvio ) for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were
More informationNovel Combination Therapies for the Treatment of Patients with Genotype 1 Hepatitis C Public Meeting
Novel Combination Therapies for the Treatment of Patients with Genotype 1 Hepatitis C Public Meeting December 18, 2014 1 CTAF Overview Core program of the Institute for Clinical and Economic Review (ICER),
More informationEVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT
Overall, perc considered that everolimus aligned with patient values. Patient advocacy group input on everolimus indicated that patients with pnets value the outcome of progression-free survival as a measure
More informationCRITICAL APPRAISAL OF CLINICAL PRACTICE GUIDELINE (CPG)
CRITICAL APPRAISAL OF CLINICAL PRACTICE GUIDELINE (CPG) Atiporn Ingsathit MD, PhD. 1 Rationale for Clinical Practice Guidelines Worldwide concerns about: Unexplained variations in clinical practice Rising
More informationTechnology appraisal guidance Published: 15 December 2010 nice.org.uk/guidance/ta211
Prucalopride for the treatment of chronic constipation in women Technology appraisal guidance Published: 15 December 2010 nice.org.uk/guidance/ta211 NICE 2018. All rights reserved. Subject to Notice of
More informationCTAF Overview. Agenda. Evidence Review. Mepolizumab (Nucala, GlaxoSmithKline plc.) for the Treatment of Severe Asthma with Eosinophilia
CTAF Overview Mepolizumab (Nucala, GlaxoSmithKline plc.) for the Treatment of Severe Asthma with Eosinophilia February 12, 2016 Core program of the Institute for Clinical and Economic Review (ICER) Goal:
More informationCognitive and Mind-Body Therapies for Chronic Low Back and Neck Pain: Effectiveness and Value
Cognitive and Mind-Body Therapies for Chronic Low Back and Neck Pain: Effectiveness and Value Evidence Report October 4, 2017 Prepared for Institute for Clinical and Economic Review, 2017 AUTHORS: Jeffrey
More informationA Primer on Health Economics & Integrating Findings from Clinical Trials into Health Technology Assessments and Decision Making
Presenter: Chris Cameron CANNeCTIN November 8, 2013 A Primer on Health Economics & Integrating Findings from Clinical Trials into Health Technology Assessments and Decision Making Acknowledgements Vanier
More informationCost-effectiveness of elosulfase alfa (Vimizim ) for the treatment of Morquio A Syndrome in patients of all ages.
Cost-effectiveness of elosulfase alfa (Vimizim ) for the treatment of Morquio A Syndrome in patients of all ages. The NCPE has issued a recommendation regarding the cost-effectiveness of elosulfase alfa
More informationperc deliberated upon: a pcodr systematic review other literature in the Clinical Guidance Report providing clinical context
require close monitoring. perc noted that induction therapy is generally administered in-hospital while consolidation therapy is administered on an out-patient basis. Because of the potential for serious
More informationpcodr EXPERT REVIEW COMMITTEE (perc) FINAL RECOMMENDATION
pcodr EXPERT REVIEW COMMITTEE (perc) FINAL RECOMMENDATION The pan-canadian Oncology Drug Review (pcodr) was established by Canada s provincial and territorial Ministries of Health (with the exception of
More informationPalm Beach Obstetrics & Gynecology, PA
Palm Beach Obstetrics & Gynecology, PA 4671 S. Congress Avenue, Lake Worth, FL 33461 561.434.0111 4631 N. Congress Avenue, Suite 102, West Palm Beach, FL 33407 Endometriosis The lining of the uterus is
More informationThe Challenge of Treating Pain
FDA Charge to the Committee: FDA Opioid Action Plan and Incorporating the Broader Public Health Impact into the Formal Risk-Benefit Assessment for Opioids Robert M. Califf, MD Commissioner of Food and
More informationCardioMEMS HF System and Sacubitril/Valsartan (Entresto ) for Management of Congestive Heart Failure Public Meeting
CardioMEMS HF System and Sacubitril/Valsartan (Entresto ) for Management of Congestive Heart Failure Public Meeting October 29, 2015 1 CTAF Overview Core program of the Institute for Clinical and Economic
More informationPalliative Care in the Outpatient Setting
Palliative Care in the Outpatient Setting Dan Ollendorf, PhD Chief Scientific Officer September 21, 2016 Contact: dollendorf@icer-review.org Disclosures ICER s reports are supported by unrestricted grants
More informationJanuary 16, Dear Administrator Verma:
Ms. Seema Verma Administrator Centers for Medicare and Medicaid Services Department of Health and Human Services Attention: CMMI New Direction P.O. Box 8011 Baltimore, MD 21244-1850 Re: (CMS-4182-P) Medicare
More informationValue-based frameworks in oncology
28 November 2017 Value-based frameworks in oncology Clarity or confusion? Prepared for: European Statistical Meeting on Latest Trends in HTA Prepared by: Jan McKendrick, Senior Director PRMA Consulting
More informationIntegrating the Patient Perspective Into Value Frameworks
Integrating the Patient Perspective Into Value Frameworks Avalere Health An Inovalon Company August, 2017 Speakers and Agenda Josh Seidman, PhD Senior Vice President jjseidman@avalere.com @jjseidman 1.
More informationPARP Inhibitors for Ovarian Cancer: Effectiveness and Value
PARP Inhibitors for Ovarian Cancer: Effectiveness and Value Draft Voting Questions for September 14, 2017 Public Meeting These questions are intended for the deliberation of the Midwest CEPAC voting body
More informationEVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT
perc deliberated upon the cost-effectiveness of lapatinib plus letrozole and discussed the challenges of using letrozole alone as a comparator and/or using trastuzumab plus anastrozole as a comparator.
More information1. Comparative effectiveness of liraglutide
Cost-effectiveness of liraglutide (Victoza ) for the treatment of adults with insufficiently controlled type 2 diabetes as an adjunct to diet and exercise. The NCPE has issued a recommendation regarding
More informationA Case for Market-Based Costs in Determining Cost-Effectiveness: The Hepatitis C Example
A Case for Market-Based Costs in Determining Cost-Effectiveness: The Hepatitis C Example Avalere Health An Inovalon Company November 2015 Executive Summary HCV Cost- Effectiveness Studies Studies assessing
More informationValue in Medicine. Why should we are about value? Conceptual Value Framework. Overview
Why should we are about value? Value in Medicine Jeffrey A. Tice, MD Professor of Medicine Division of General Internal Medicine Value based payments by insurers Health care cost increases are unsustainable
More informationAccess to newly licensed medicines. Scottish Medicines Consortium
Access to newly licensed medicines Scottish Medicines Consortium Modifiers The Committee has previously been provided with information about why the SMC uses modifiers in its appraisal process and also
More informationShaping our future: a call to action to tackle the diabetes epidemic and reduce its economic impact
Shaping our future: a call to action to tackle the diabetes epidemic and reduce its economic impact Task Force for the National Conference on Diabetes: The Task Force is comprised of Taking Control of
More informationCost-effectiveness of apremilast (Otezla )
Cost-effectiveness of apremilast (Otezla ) alone or in combination with Disease Modifying Antirheumatic Drugs (DMARDs) for the treatment of active psoriatic arthritis in adult patients who have had an
More informationCost-effectiveness of evolocumab (Repatha ) for hypercholesterolemia
Cost-effectiveness of evolocumab (Repatha ) for hypercholesterolemia The NCPE has issued a recommendation regarding the cost-effectiveness of evolocumab (Repatha ). Following NCPE assessment of the applicant
More informationControversies in Obesity Management
Controversies in Obesity Management A Technology Assessment Final Report August 10, 2015 Completed by: Institute for Clinical and Economic Review Institute for Clinical and Economic Review, 2015 AUTHORS:
More informationA Technology Assessment. Final Report. January 30, Completed by: Institute for Clinical and Economic Review
The Comparative Clinical Effectiveness and Value of Novel Combination Therapies for the Treatment of Patients with Genotype 1 Chronic Hepatitis C Infection A Technology Assessment Final Report January
More informationClinical Policy: Goserelin Acetate (Zoladex) Reference Number: ERX.SPA.145 Effective Date:
Clinical Policy: (Zoladex) Reference Number: ERX.SPA.145 Effective Date: 10.01.16 Last Review Date: 11.17 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationIn keeping with the Scottish Diabetes Group criteria, use should be restricted to those who:
Advice Statement 009-18 July 2018 Advice Statement What is the clinical and cost effectiveness of Freestyle Libre flash glucose monitoring for patients with diabetes mellitus treated with intensive insulin
More informationAntiandrogen Therapies for Nonmetastatic Castration-Resistant Prostate Cancer: Effectiveness and Value
Antiandrogen Therapies for Nonmetastatic Castration-Resistant Prostate Cancer: Effectiveness and Value Final Evidence Report October 4, 2018 Prepared for Institute for Clinical and Economic Review, 2018
More informationREAD THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION ORILISSA. elagolix (as elagolix sodium) tablets
READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION ORILISSA elagolix (as elagolix sodium) tablets Read this carefully before you start taking ORILISSA and each time you
More informationPanel Value Frameworks for Cancer Therapies: Are they Useful in the Context of Canadian Health Technology Assessments and Reimbursement Decisions?
Panel Value Frameworks for Cancer Therapies: Are they Useful in the Context of Canadian Health Technology Assessments and Reimbursement Decisions? 2017 CADTH Symposium Ottawa, April, 24th, 2017 Reiner
More informationrisks. Therefore, perc agreed that the reimbursement criteria should match the eligibility criteria of the SELECT trial.
risks. Therefore, perc agreed that the reimbursement criteria should match the eligibility criteria of the SELECT trial. perc considered input from one patient advocacy group indicating that patients value
More informationCanakinumab for Atherosclerotic Cardiovascular Disease: Effectiveness and Value
Canakinumab for Atherosclerotic Cardiovascular Disease: Effectiveness and Value Final Background and Scope August 30, 2018 Background Atherosclerotic cardiovascular disease (ASCVD) is the most common cause
More informationMeasuring outcomes to improve the management of continence care. Dr Adrienne Rivlin KPMG Global Strategy Group
Measuring outcomes to improve the management of continence care Dr Adrienne Rivlin KPMG Global Strategy Group Background of the study Many treatment options, few find a cure High quality daily continence
More informationEconomic and societal impact of direct-acting antiviral therapy in Hepatitis C Zoltán Kaló
Economic and societal impact of directacting antiviral therapy in Hepatitis C Zoltán Kaló Professor of Health Economics ISPOR 19th Annual European Congress November 2 nd 2016 ATHCV16099925102016 Concerns
More informationQoL compared with ADT plus placebo. perc considered this to be reasonable in the nmcrpc setting, where patients QoL is expected to be relatively high and stable. perc discussed that there is a net clinical
More informationClinical Policy: Goserelin Acetate (Zoladex) Reference Number: CP.PHAR.171 Effective Date: Last Review Date: Line of Business: Medicaid
Clinical Policy: (Zoladex) Reference Number: CP.PHAR.171 Effective Date: 10.01.16 Last Review Date: 11.17 Line of Business: Medicaid Coding Implications Revision Log See Important Reminder at the end of
More informationTechnology appraisal guidance Published: 30 August 2017 nice.org.uk/guidance/ta471
Eluxadoline for treating irritable bowel syndrome with diarrhoea Technology appraisal guidance Published: 30 August 2017 nice.org.uk/guidance/ta471 NICE 2017. All rights reserved. Subject to Notice of
More informationStrategies for Federal Agencies
Confronting Pain Management and the Opioid Epidemic Strategies for Federal Agencies Over the past 25 years, the United States has experienced a dramatic increase in deaths from opioid overdose, opioid
More informationUpdate on PARP inhibitors
Professor of Medicine Harvard Medical School Boston MA Update on PARP inhibitors Ursula Matulonis, M.D. Chief, Division of Gynecologic Oncology Brock-Wilson Family Chair Dana-Farber Cancer Institute History
More informationManagement Options for Opioid Dependence:
Management Options for Opioid Dependence: Policy Implications and Recommendations Dan Ollendorf, PhD Sarah Jane Reed, MSc New England CEPAC Goal: To improve the application of evidence to guide practice
More informationTask Force Finding and Rationale Statement
Cardiovascular Disease Prevention and Control: Reducing Out-of- Pocket Costs for Cardiovascular Disease Preventive Services for Patients with High Blood Pressure and High Cholesterol Task Force Finding
More informationNICE decisions on health care provisions in England
NICE decisions on health care provisions in England Matt Stevenson, Professor of Health Technology Assessment (HTA), ScHARR, University of Sheffield, UK A quick introduction I am Technical Director of
More informationObeticholic Acid for the Treatment of Primary Biliary Cholangitis: Comparative Clinical Effectiveness, Value, and Value-Based Price Benchmarks
Obeticholic Acid for the Treatment of Primary Biliary Cholangitis: Comparative Clinical Effectiveness, Value, and Value-Based Price Benchmarks Evidence Report July 26, 2016 Institute for Clinical and Economic
More informationSetting The setting was primary and secondary care. The economic study was carried out in the USA.
Cost-effectiveness of pap smear screening for vaginal cancer after total hysterectomy for benign disease Fetters M D, Lieberman R W, Abrahamse P H, Sanghvi R V, Sonnad S S Record Status This is a critical
More informationThe pcodr review also provided contextual information on ALK mutation testing.
only approximately 4% of NSCLC patients are expected to have the ALK mutation. perc further discussed these estimates in the context of the feasibility of implementing a funding recommendation for crizotinib.
More informationTechnology appraisal guidance Published: 28 June 2017 nice.org.uk/guidance/ta448
Etelcalcetide for treating secondary hyperparathyroidism Technology appraisal guidance Published: 28 June 2017 nice.org.uk/guidance/ta448 NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
More informationpcodr EXPERT REVIEW COMMITTEE (perc) INITIAL RECOMMENDATION
pcodr EXPERT REVIEW COMMITTEE (perc) INITIAL RECOMMENDATION The pan-canadian Oncology Drug Review (pcodr) was established by Canada s provincial and territorial Ministries of Health (with the exception
More informationCost-effectiveness of Daratumumab (Darzalex ) for the Treatment of Adult Patients with Relapsed and Refractory Multiple Myeloma.
Cost-effectiveness of Daratumumab (Darzalex ) for the Treatment of Adult Patients with Relapsed and Refractory Multiple Myeloma. The NCPE has issued a recommendation regarding the cost-effectiveness of
More informationCITIZEN BRIEF MAKING FAIR AND SUSTAINABLE DECISIONS ABOUT FUNDING FOR CANCER DRUGS IN CANADA
CITIZEN BRIEF MAKING FAIR AND SUSTAINABLE DECISIONS ABOUT FUNDING FOR CANCER DRUGS IN CANADA 29-30 OCTOBER 2016 Making Fair and Sustainable Decisions about Funding for Cancer Drugs in Canada McMaster Health
More informationCost-effectiveness of androgen suppression therapies in advanced prostate cancer Bayoumi A M, Brown A D, Garber A M
Cost-effectiveness of androgen suppression therapies in advanced prostate cancer Bayoumi A M, Brown A D, Garber A M Record Status This is a critical abstract of an economic evaluation that meets the criteria
More informationMinimizing Cost per Quality-Adjusted Life Year Gained?
Minimizing Cost per Quality-Adjusted Life Year Gained? Contribution to Issue Panel: The Controversial Role of Cost Effectiveness Analyses and Incremental Cost Effectiveness Ratio (ICER) Thresholds in Value-Based
More informationCost-effectiveness of evolocumab (Repatha ) for primary hypercholesterolemia and mixed dyslipidemia.
Cost-effectiveness of evolocumab (Repatha ) for primary hypercholesterolemia and mixed dyslipidemia. The NCPE has issued a recommendation regarding the cost-effectiveness of evolocumab (Repatha ) Following
More informationLearning Objectives. Peri menopause. Menopause Overview. Recommendation grading categories
Learning Objectives Identify common symptoms of the menopause transition Understand the risks and benefits of hormone replacement therapy (HRT) Be able to choose an appropriate hormone replacement regimen
More informationModeling the annual costs of postmenopausal prevention therapy: raloxifene, alendronate, or estrogen-progestin therapy Mullins C D, Ohsfeldt R L
Modeling the annual costs of postmenopausal prevention therapy: raloxifene, alendronate, or estrogen-progestin therapy Mullins C D, Ohsfeldt R L Record Status This is a critical abstract of an economic
More informationrosuvastatin, 5mg, 10mg, 20mg, film-coated tablets (Crestor ) SMC No. (725/11) AstraZeneca UK Ltd.
rosuvastatin, 5mg, 10mg, 20mg, film-coated tablets (Crestor ) SMC No. (725/11) AstraZeneca UK Ltd. 09 September 2011 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product
More informationthe cumulative rates of persistence with estrogen replacement therapy, CEE/MPA and tibolone;
Economic impact of tibolone compared with continuous-combined hormone replacement therapy in the management of climacteric symptoms in postmenopausal women Diaby V, Perreault S, Lachaine J Record Status
More informationSafe Harbor Statement
Safe Harbor Statement These slides contain forward-looking statements based on estimates and assumptions by our management that, although we believe to be reasonable, are inherently uncertain. Forward-looking
More informationStatus Update on the National Cardiovascular Prevention Guidelines - JNC 8, ATP 4, and Obesity 2
TABLE OF CONTENTS Status Update on the National Cardiovascular Prevention Guidelines 1 Drosperinone-Containing Oral Contraceptives and Venous Thromboembolism Risk 1-4 P&T Committee Formulary Action 5 Status
More informationProphylaxis for Hereditary Angioedema with Lanadelumab and C1 Inhibitors: Effectiveness and Value
Prophylaxis for Hereditary Angioedema with Lanadelumab and C1 Inhibitors: Effectiveness and Value Final Evidence Report November 15, 2018 Prepared for Institute for Clinical and Economic Review, 2018 ICER
More informationSubmitted to the House Energy and Commerce Committee. Federal Efforts to Combat the Opioid Crisis
STATEMENT FOR THE RECORD Submitted to the House Energy and Commerce Committee Federal Efforts to Combat the Opioid Crisis October 25, 2017 America s Health Insurance Plans 601 Pennsylvania Avenue, NW Suite
More informationCost-benefit analysis of first-void urine Chlamydia trachomatis screening program Paavonen J, Puolakkainen M, Paukku M, Sintonen H
Cost-benefit analysis of first-void urine Chlamydia trachomatis screening program Paavonen J, Puolakkainen M, Paukku M, Sintonen H Record Status This is a critical abstract of an economic evaluation that
More informationResults of implication of aromatase inhibitors in therapy of genital endometriosis Yarmolinskaya M. (Speaker), Bezhenar V., Molotkov A.
Results of implication of aromatase inhibitors in therapy of genital endometriosis Yarmolinskaya M. (Speaker), Bezhenar V., Molotkov A. Ott's Research Institute of Obstetrics, Gynecology and Reproductology,
More informationWELCOME HEPATITIS C DRUGS - EVIDENCE TO DEMONSTRATE EFFECTIVENESS & VALUE
WELCOME HEPATITIS C DRUGS - EVIDENCE TO DEMONSTRATE EFFECTIVENESS & VALUE July 7 th, 2014 ABOUT CMTP AND ICER The Center for Medical Technology Policy (CMTP) has extensive experience convening stakeholder
More informationNo one should be at risk of poor health because of their social and economic situations.
HEALTH MATTERS No one should be at risk of poor health because of their social and economic situations. Members of municipal government play an important role in shaping policies that impact all aspects
More informationpcodr EXPERT REVIEW COMMITTEE (perc) FINAL RECOMMENDATION
pcodr EXPERT REVIEW COMMITTEE (perc) FINAL RECOMMENDATION The pan-canadian Oncology Drug Review (pcodr) was established by Canada s provincial and territorial Ministries of Health (with the exception of
More informationEVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT
into consideration the concerns of the patient. Upon reconsideration of the perc Initial Recommendation,the Committee discussed feedback from the patient advocacy group reporting concerns that the definition
More informationBiologic Therapies for Treatment of Asthma Associated with Type 2 Inflammation: Effectiveness, Value, and Value-Based Price Benchmarks
Biologic Therapies for Treatment of Asthma Associated with Type 2 Inflammation: Effectiveness, Value, and Value-Based Price Benchmarks Final Background and Scope June 13, 2018 Background The Centers for
More informationCost-effectiveness of osimertinib (Tagrisso )
Cost-effectiveness of osimertinib (Tagrisso ) for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small-cell lung
More informationThe Journey towards Total Wellbeing A Health System s Innovative Approach
The Journey towards Total Wellbeing A Health System s Innovative Approach Company Profile Wellness A state of complete physical, mental and social wellbeing and not merely the absence of disease or infirmity
More information